Chip designer AMD said Wednesday that it will invest $20 million in Absci, the Vancouver company that aims to use artificial ...

AI drug creation company Absci Corporation (NASDAQ:ABSI) shares are trading higher in premarket on Wednesday after the ...

Absci (ABSI) and Owkin announced a partnership bringing together two leading AI platforms to rapidly discover and design ...

The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other ...

Absci (NASDAQ:ABSI – Free Report) had its price objective cut by KeyCorp from $6.00 to $5.00 in a research note released on Wednesday,Benzinga reports. They currently have an overweight rating on the ...

Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop ...

Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics ...

Investing.com -- Shares of Absci Corporation (NASDAQ: ABSI) soared 50% following the announcement of a strategic ...

Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration ...

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on AbSci (ABSI – Research Report) and keeping the price target at ...

Absci (ABSI) was rising after a media report on a $20M investment by the semiconductor company Advanced Micro Devices (AMD) in the AI drug creation company.

Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that followed a six-month decline in the stock price.